- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Hu-manity.co and IBM Partner for Personal Data Property Rights
Hu-manity.co, the organization developing human rights and corollary sovereign laws in a decentralized manner on blockchains, announced it will use IBM’s Blockchain Platform technology for its global consent ledger. Using IBM’s platform, Hu-manity.co will give people control to manage consent, authorization, and commercial use of their personal information via a permissioned blockchain-based data marketplace.
Consumers can claim their human data rights via Hu-manity.co’s #My31 iPhone and Android app built on IBM Blockchain. Some capabilities include users can choose to share no information with third parties, or they may want to provide consent for use of their medical data for cancer research only. Users can also choose to lease their data to pharmaceutical companies or data aggregators but only upon receiving fair market compensation.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
